214 related articles for article (PubMed ID: 12405867)
1. Pharmacokinetics of ciprofloxacin as a tool to optimise dosage schedules in community patients.
Sánchez Navarro MD; Coloma Milano C; Zarzuelo Castañeda A; Sayalero Marinero ML; Sánchez-Navarro A
Clin Pharmacokinet; 2002; 41(14):1213-20. PubMed ID: 12405867
[TBL] [Abstract][Full Text] [Related]
2. Comparison of sparfloxacin and ciprofloxacin in the treatment of community-acquired acute uncomplicated urinary tract infection in women. Sparfloxacin Multicenter Uncomplicated Urinary Tract Infection Study Group.
Henry DC; Nenad RC; Iravani A; Tice AD; Mansfield DL; Magner DJ; Dorr MB; Talbot GH
Clin Ther; 1999 Jun; 21(6):966-81. PubMed ID: 10440621
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of ciprofloxacin XR (1000 mg) versus levofloxacin (500 mg) in plasma and urine of male and female healthy volunteers receiving a single oral dose.
Wagenlehner FM; Kinzig-Schippers M; Tischmeyer U; Wagenlehner C; Sörgel F; Dalhoff A; Naber KG
Int J Antimicrob Agents; 2006 Jan; 27(1):7-14. PubMed ID: 16343856
[TBL] [Abstract][Full Text] [Related]
4. Ciprofloxacin disposition in elderly patients with LRTI being treated with sequential therapy (200 mg intravenously twice daily followed by 500 mg per os twice daily): comparative pharmacokinetics and the role of therapeutic drug monitoring.
Pea F; Milaneschi R; Baraldo M; Lugatti E; Talmassons G; Furlanut M
Ther Drug Monit; 2000 Aug; 22(4):386-91. PubMed ID: 10942176
[TBL] [Abstract][Full Text] [Related]
5. Antibiotic dosing issues in lower respiratory tract infection: population-derived area under inhibitory curve is predictive of efficacy.
Highet VS; Forrest A; Ballow CH; Schentag JJ
J Antimicrob Chemother; 1999 Mar; 43 Suppl A():55-63. PubMed ID: 10225573
[TBL] [Abstract][Full Text] [Related]
6. Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study.
van Zanten AR; Polderman KH; van Geijlswijk IM; van der Meer GY; Schouten MA; Girbes AR
J Crit Care; 2008 Sep; 23(3):422-30. PubMed ID: 18725050
[TBL] [Abstract][Full Text] [Related]
7. Plasma concentrations of enrofloxacin and its active metabolite ciprofloxacin in dogs following single oral administration of enrofloxacin at 7.5, 10, or 20 mg/kg.
Boothe DM; Boeckh A; Boothe HW; Wilkie S; Jones S
Vet Ther; 2002; 3(4):409-19. PubMed ID: 12584678
[TBL] [Abstract][Full Text] [Related]
8. Enrichment of resistant Staphylococcus aureus at ciprofloxacin concentrations simulated within the mutant selection window: bolus versus continuous infusion.
Firsov AA; Smirnova MV; Strukova EN; Vostrov SN; Portnoy YA; Zinner SH
Int J Antimicrob Agents; 2008 Dec; 32(6):488-93. PubMed ID: 18790614
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic/pharmacodynamic modelling of ciprofloxacin 250 mg/12 h versus 500 mg/24 h for urinary infections.
Sánchez Navarro MD; Sayalero Marinero ML; Sánchez Navarro A
J Antimicrob Chemother; 2002 Jul; 50(1):67-72. PubMed ID: 12096008
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic-pharmacodynamic analysis of ciprofloxacin in elderly Chinese patients with lower respiratory tract infections caused by Gram-negative bacteria.
Gai XY; Bo SN; Shen N; Zhou QT; Yin AY; Lu W
Chin Med J (Engl); 2019 Mar; 132(6):638-646. PubMed ID: 30855292
[TBL] [Abstract][Full Text] [Related]
11. Predictors of bacterial resistance using in vitro dynamic models: area under the concentration-time curve related to either the minimum inhibitory or mutant prevention antibiotic concentration.
Strukova EN; Portnoy YA; Zinner SH; Firsov AA
J Antimicrob Chemother; 2016 Mar; 71(3):678-84. PubMed ID: 26626718
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections.
Moise-Broder PA; Forrest A; Birmingham MC; Schentag JJ
Clin Pharmacokinet; 2004; 43(13):925-42. PubMed ID: 15509186
[TBL] [Abstract][Full Text] [Related]
13. The influence of age and gender on the pharmacokinetics of moxifloxacin.
Sullivan JT; Lettieri JT; Liu P; Heller AH
Clin Pharmacokinet; 2001; 40 Suppl 1():11-8. PubMed ID: 11352437
[TBL] [Abstract][Full Text] [Related]
14. Urinary excretion and bactericidal activity of intravenous ciprofloxacin compared with oral ciprofloxacin.
Naber KG; Theuretzbacher U; Moneva-Koucheva G; Stass H
Eur J Clin Microbiol Infect Dis; 1999 Nov; 18(11):783-9. PubMed ID: 10614952
[TBL] [Abstract][Full Text] [Related]
15. Are ciprofloxacin dosage regimens adequate for antimicrobial efficacy and prevention of resistance? Pseudomonas aeruginosa bloodstream infection in elderly patients as a simulation case study.
Cazaubon Y; Bourguignon L; Goutelle S; Martin O; Maire P; Ducher M
Fundam Clin Pharmacol; 2015 Dec; 29(6):615-24. PubMed ID: 26406268
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.
Montgomery MJ; Beringer PM; Aminimanizani A; Louie SG; Shapiro BJ; Jelliffe R; Gill MA
Antimicrob Agents Chemother; 2001 Dec; 45(12):3468-73. PubMed ID: 11709326
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic/pharmacodynamic (PK/PD) evaluation of a once-daily treatment using ciprofloxacin in an extended-release dosage form.
Schuck EL; Dalhoff A; Stass H; Derendorf H
Infection; 2005 Dec; 33 Suppl 2():22-8. PubMed ID: 16518708
[TBL] [Abstract][Full Text] [Related]
18. High interindividual variability in urinary fosfomycin concentrations in healthy female volunteers.
Wijma RA; Koch BCP; van Gelder T; Mouton JW
Clin Microbiol Infect; 2018 May; 24(5):528-532. PubMed ID: 28867662
[TBL] [Abstract][Full Text] [Related]
19. Effect of Multi Drug Resistance Protein 4 (MRP4) Inhibition on the Pharmacokinetics and Pharmacodynamics of Ciprofloxacin in Normal and Rats with LPS-Induced Inflammation.
Prasad VG; Achanta S; Tammineni YR; Alla GR; Thirtham MR; Rao GS
Eur J Drug Metab Pharmacokinet; 2016 Dec; 41(6):733-741. PubMed ID: 26458556
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of a novel extended-release ciprofloxacin in healthy volunteers.
Washington CB; Hou SY; Campanella C; Hughes N; Brown S; Berner B
J Clin Pharmacol; 2005 Nov; 45(11):1236-44. PubMed ID: 16239356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
